Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High Risk Myelodysplastic Syndrome

NCT04402541 is registered in ClinicalTrials.gov with Cleave Therapeutics, Inc. as lead sponsor.

NCT NCT04402541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04402541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profiles of CB-5339 in Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Intermediate or High Risk Myelodysplastic Syndrome
Lead sponsor
Cleave Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
June 8, 2020
Completion date
July 23, 2023
Enrollment
55 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, in relapse, myelodysplastic syndromes